Diabetic Med:患有前驱糖尿病的青少年的心血管危险因素

2018-11-01 MedSci MedSci原创

近日,国际杂志 《Diabetic Med》上在线发表一项关于患有前驱糖尿病的青少年的心血管危险因素的研究。 患有2型糖尿病的青少年更可能有心血管疾病(CVD)风险因素,但在患有前驱糖尿病的青少年中关于此类的数据目前仍然很少。研究人员描述了美国患有前驱糖尿病的青少年的CVD危险因素,并将这些风险因素的水平与正常葡萄糖的青少年进行了比较。 2005-2014年全国健康和营养检查调查是一

近日,国际杂志 《Diabetic Med》上在线发表一项关于患有前驱糖尿病的青少年的血管危险因素的研究。

患有2糖尿病的青少年更可能有血管疾病(CVD)风险因素,但在患有前驱糖尿病的青少年中关于此类的数据目前仍然很少。研究人员描述了美国患有前驱糖尿病的青少年的CVD危险因素,并将这些风险因素的水平与正常葡萄糖的青少年进行了比较。

2005-2014年全国健康和营养检查调查是一项具有全国代表性的横断面调查,其中包括年龄在12-19岁排除糖尿病的2843名的青少年。前驱糖尿病基于HbA 1c,空腹血浆葡萄糖或2小时血浆葡萄糖。研究人员使用适合年龄的临界点确定了青少年的心脏代谢风险因素。同时还计算了与正常血糖水平相比,与前驱糖尿病相关的这些结果的优势比(OR)和95%可信区间(CI)。

研究显示,前驱糖尿病的加权患病率为17.4%。校正后,前驱糖尿病(与正常葡萄糖相比)与肥胖(OR 1.86,95CI 1.35-2.55),低HDL-胆固醇OR 1.62,95CI 1.08-2.44),高甘油三酯(OR 1.61,95%) CI 1.12-2.30)和肝转氨酶升高(OR 2.09,95CI 1.19-3.67)相关,但与高血压OR 1.77,95CI 0.88-3.54),总胆固醇升高(OR 1.30,95CI 0.82-2.06 ),LDL-胆固醇升高(OR 1.59,95CI 0.88-2.88)或白蛋白尿(OR 1.24,95CI 0.76-2.02)无关。

研究表明,与葡萄糖正常的青少年相比,患有前驱糖尿病的美国青少年更容易患有肥胖,低HDL-胆固醇,高甘油三酯和升高的肝转氨酶。寻找青年时期的前驱糖尿病对于预防2型糖尿病和长期合并症非常重要。

原始出处:

S. S. CasagrandeA. MenkeB. Linderet al. Cardiovascular risk factors in adolescents with prediabetes

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1970659, encodeId=bae519e065945, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Wed Jan 30 12:42:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760875, encodeId=d82b1e608752b, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Dec 04 00:42:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638835, encodeId=ecfc1638835f3, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Mar 24 23:42:00 CST 2019, time=2019-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948932, encodeId=016c19489323f, content=<a href='/topic/show?id=1e4789584b0' target=_blank style='color:#2F92EE;'>#血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89584, encryptionId=1e4789584b0, topicName=血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Nov 07 01:42:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331492, encodeId=7203133149200, content=<a href='/topic/show?id=afab51e831d' target=_blank style='color:#2F92EE;'>#心血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51783, encryptionId=afab51e831d, topicName=心血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Sat Nov 03 05:42:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609276, encodeId=f08316092e6bc, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Nov 03 05:42:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629778, encodeId=a24b1629e7835, content=<a href='/topic/show?id=28c351e80dc' target=_blank style='color:#2F92EE;'>#心血管危险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51780, encryptionId=28c351e80dc, topicName=心血管危险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e0221357465, createdName=lingaifan, createdTime=Sat Nov 03 05:42:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042004, encodeId=e7d5104200435, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Nov 01 17:42:00 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1970659, encodeId=bae519e065945, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Wed Jan 30 12:42:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760875, encodeId=d82b1e608752b, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Dec 04 00:42:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638835, encodeId=ecfc1638835f3, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Mar 24 23:42:00 CST 2019, time=2019-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948932, encodeId=016c19489323f, content=<a href='/topic/show?id=1e4789584b0' target=_blank style='color:#2F92EE;'>#血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89584, encryptionId=1e4789584b0, topicName=血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Nov 07 01:42:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331492, encodeId=7203133149200, content=<a href='/topic/show?id=afab51e831d' target=_blank style='color:#2F92EE;'>#心血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51783, encryptionId=afab51e831d, topicName=心血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Sat Nov 03 05:42:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609276, encodeId=f08316092e6bc, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Nov 03 05:42:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629778, encodeId=a24b1629e7835, content=<a href='/topic/show?id=28c351e80dc' target=_blank style='color:#2F92EE;'>#心血管危险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51780, encryptionId=28c351e80dc, topicName=心血管危险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e0221357465, createdName=lingaifan, createdTime=Sat Nov 03 05:42:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042004, encodeId=e7d5104200435, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Nov 01 17:42:00 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1970659, encodeId=bae519e065945, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Wed Jan 30 12:42:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760875, encodeId=d82b1e608752b, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Dec 04 00:42:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638835, encodeId=ecfc1638835f3, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Mar 24 23:42:00 CST 2019, time=2019-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948932, encodeId=016c19489323f, content=<a href='/topic/show?id=1e4789584b0' target=_blank style='color:#2F92EE;'>#血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89584, encryptionId=1e4789584b0, topicName=血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Nov 07 01:42:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331492, encodeId=7203133149200, content=<a href='/topic/show?id=afab51e831d' target=_blank style='color:#2F92EE;'>#心血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51783, encryptionId=afab51e831d, topicName=心血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Sat Nov 03 05:42:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609276, encodeId=f08316092e6bc, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Nov 03 05:42:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629778, encodeId=a24b1629e7835, content=<a href='/topic/show?id=28c351e80dc' target=_blank style='color:#2F92EE;'>#心血管危险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51780, encryptionId=28c351e80dc, topicName=心血管危险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e0221357465, createdName=lingaifan, createdTime=Sat Nov 03 05:42:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042004, encodeId=e7d5104200435, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Nov 01 17:42:00 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1970659, encodeId=bae519e065945, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Wed Jan 30 12:42:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760875, encodeId=d82b1e608752b, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Dec 04 00:42:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638835, encodeId=ecfc1638835f3, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Mar 24 23:42:00 CST 2019, time=2019-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948932, encodeId=016c19489323f, content=<a href='/topic/show?id=1e4789584b0' target=_blank style='color:#2F92EE;'>#血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89584, encryptionId=1e4789584b0, topicName=血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Nov 07 01:42:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331492, encodeId=7203133149200, content=<a href='/topic/show?id=afab51e831d' target=_blank style='color:#2F92EE;'>#心血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51783, encryptionId=afab51e831d, topicName=心血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Sat Nov 03 05:42:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609276, encodeId=f08316092e6bc, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Nov 03 05:42:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629778, encodeId=a24b1629e7835, content=<a href='/topic/show?id=28c351e80dc' target=_blank style='color:#2F92EE;'>#心血管危险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51780, encryptionId=28c351e80dc, topicName=心血管危险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e0221357465, createdName=lingaifan, createdTime=Sat Nov 03 05:42:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042004, encodeId=e7d5104200435, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Nov 01 17:42:00 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1970659, encodeId=bae519e065945, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Wed Jan 30 12:42:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760875, encodeId=d82b1e608752b, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Dec 04 00:42:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638835, encodeId=ecfc1638835f3, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Mar 24 23:42:00 CST 2019, time=2019-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948932, encodeId=016c19489323f, content=<a href='/topic/show?id=1e4789584b0' target=_blank style='color:#2F92EE;'>#血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89584, encryptionId=1e4789584b0, topicName=血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Nov 07 01:42:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331492, encodeId=7203133149200, content=<a href='/topic/show?id=afab51e831d' target=_blank style='color:#2F92EE;'>#心血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51783, encryptionId=afab51e831d, topicName=心血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Sat Nov 03 05:42:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609276, encodeId=f08316092e6bc, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Nov 03 05:42:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629778, encodeId=a24b1629e7835, content=<a href='/topic/show?id=28c351e80dc' target=_blank style='color:#2F92EE;'>#心血管危险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51780, encryptionId=28c351e80dc, topicName=心血管危险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e0221357465, createdName=lingaifan, createdTime=Sat Nov 03 05:42:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042004, encodeId=e7d5104200435, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Nov 01 17:42:00 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1970659, encodeId=bae519e065945, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Wed Jan 30 12:42:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760875, encodeId=d82b1e608752b, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Dec 04 00:42:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638835, encodeId=ecfc1638835f3, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Mar 24 23:42:00 CST 2019, time=2019-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948932, encodeId=016c19489323f, content=<a href='/topic/show?id=1e4789584b0' target=_blank style='color:#2F92EE;'>#血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89584, encryptionId=1e4789584b0, topicName=血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Nov 07 01:42:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331492, encodeId=7203133149200, content=<a href='/topic/show?id=afab51e831d' target=_blank style='color:#2F92EE;'>#心血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51783, encryptionId=afab51e831d, topicName=心血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Sat Nov 03 05:42:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609276, encodeId=f08316092e6bc, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Nov 03 05:42:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629778, encodeId=a24b1629e7835, content=<a href='/topic/show?id=28c351e80dc' target=_blank style='color:#2F92EE;'>#心血管危险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51780, encryptionId=28c351e80dc, topicName=心血管危险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e0221357465, createdName=lingaifan, createdTime=Sat Nov 03 05:42:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042004, encodeId=e7d5104200435, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Nov 01 17:42:00 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1970659, encodeId=bae519e065945, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Wed Jan 30 12:42:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760875, encodeId=d82b1e608752b, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Dec 04 00:42:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638835, encodeId=ecfc1638835f3, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Mar 24 23:42:00 CST 2019, time=2019-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948932, encodeId=016c19489323f, content=<a href='/topic/show?id=1e4789584b0' target=_blank style='color:#2F92EE;'>#血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89584, encryptionId=1e4789584b0, topicName=血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Nov 07 01:42:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331492, encodeId=7203133149200, content=<a href='/topic/show?id=afab51e831d' target=_blank style='color:#2F92EE;'>#心血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51783, encryptionId=afab51e831d, topicName=心血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Sat Nov 03 05:42:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609276, encodeId=f08316092e6bc, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Nov 03 05:42:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629778, encodeId=a24b1629e7835, content=<a href='/topic/show?id=28c351e80dc' target=_blank style='color:#2F92EE;'>#心血管危险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51780, encryptionId=28c351e80dc, topicName=心血管危险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e0221357465, createdName=lingaifan, createdTime=Sat Nov 03 05:42:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042004, encodeId=e7d5104200435, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Nov 01 17:42:00 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1970659, encodeId=bae519e065945, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Wed Jan 30 12:42:00 CST 2019, time=2019-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760875, encodeId=d82b1e608752b, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Dec 04 00:42:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638835, encodeId=ecfc1638835f3, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Mar 24 23:42:00 CST 2019, time=2019-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948932, encodeId=016c19489323f, content=<a href='/topic/show?id=1e4789584b0' target=_blank style='color:#2F92EE;'>#血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89584, encryptionId=1e4789584b0, topicName=血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Nov 07 01:42:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331492, encodeId=7203133149200, content=<a href='/topic/show?id=afab51e831d' target=_blank style='color:#2F92EE;'>#心血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51783, encryptionId=afab51e831d, topicName=心血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Sat Nov 03 05:42:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609276, encodeId=f08316092e6bc, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Nov 03 05:42:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629778, encodeId=a24b1629e7835, content=<a href='/topic/show?id=28c351e80dc' target=_blank style='color:#2F92EE;'>#心血管危险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51780, encryptionId=28c351e80dc, topicName=心血管危险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e0221357465, createdName=lingaifan, createdTime=Sat Nov 03 05:42:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042004, encodeId=e7d5104200435, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Nov 01 17:42:00 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
    2018-11-01 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

JACC:缺血性心脏病危险因素的控制与生存率

单个危险因素的控制可以提高稳定性缺血性心脏病(SIHD)的生存率,但是多重危险因素的控制是否会增加生存率尚不清楚。本研究的目的旨在评估大量危险因素的控制与SIHD患者生存率的关系。在2287名COURAGE临床试验的人群中,2102(92%)名患者接受有6大危险因素(收缩压、低密度脂蛋白胆固醇、抽烟、体育锻炼、饮食和BMI)的评估,主要终点事件是死亡率。经过平均6.8年时间的随访,473 (22.

JACC:健康人群心肺健康状况与死亡率的相关性研究

心肺健康(CRF)和死亡率的关系已经有许多研究证实,然而大部分研究都是通过估计CRF得出的结论。本研究的目的旨在健康人群中通过心肺运动(CPX)测试评估心肺健康与全因、心血管和癌症死亡率的关系。本研究纳入了4137名健康对象(男性为2326名,女性为1811名,平均年龄42.8 ± 12.2岁),并通过CPX检测了基线的CRF水平,经过24.2 ± 11.7年时间的随访,评估了死亡率。随访期间,7

盘点:JACC十月第五期研究一览

1. 经皮导管主动脉瓣置换术在低外科风险患者中同样安全有效DOI: 10.1016/j.jacc.2018.08.1033http://www.onlinejacc.org/content/72/18经导管主动脉瓣置换术(TAVR)目前是高风险外科主动脉瓣置换术(SAVR)有临床症状的严重主动脉瓣狭窄患者的标准治疗方法。本研究的目的旨在评估TAVR在低风险患者中的作用。本研究纳入了低风险TAV

JACC:严重肢体缺血的外周动脉疾病患者的动脉病理变化

严重的肢体缺血(CLI)是外周动脉疾病(PAD)的主要并发症之一。本研究的目的旨在评估CLI患者膝盖上和膝盖下标本的PAD病理变化。本研究共纳入了95例外周动脉疾病患者的121个截肢标本,其中75例患者存在CLI,截肢标本的股动脉和腘动脉(FEM-POP)与膝下动脉(INFRA-POP)被单独进行病理分析。最终共分析了299条动脉,在239条来自CLI患者的动脉中,动脉粥样斑块在FEM-POP中更

JACC:可溶性肿瘤因子2抑制剂可预测慢性心衰预后

可溶性肿瘤因子2抑制剂(sST2)是一种炎症和纤维化的生物标志物。本研究的目的旨在评估sST2在慢性心衰中的预测价值。本研究共纳入了4268名患者(平均年龄为68岁,男性占75%,65%为缺血性心衰,87%为左室射血分数(LVEF)<40%),其NT-proBNP、hs-TnT和sST2的水平分别是1,360 ng/l (四分位数区间:513 -3,222 ng/l), 18 ng/l (四分位数

CLIN CHEM:分析蛋白质组学发现的标志物和验证肝素给药对心血管生物标志物分析的混淆效应

一些血浆蛋白被认为是多种心血管疾病的标志物,但在独立的患者队列中情况却并非如此。这可能与药物对血浆蛋白浓度的干扰有关。研究人员使用蛋白质组学来鉴定血浆蛋白,这些蛋白的浓度随肝素的使用而改变,因此在使用肝素的情况下,它们作为生物标志物的评估可能会出现混淆。 研究人员使用了蛋白质组学的方法根据等压标签和nano-LC-MS / MS分析量化几百种蛋白质,个体血浆样本来自9例血管内超声随访12个月